A regular Meeting of Shareholders of Farmak JSC was held on March 19, 2014.
Director General of Farmak JSC, Filya Zhebrovska, spoke at the meeting of the participants reporting on the Company’s activities in the year 2013 and covering the main development activities of Farmak JSC for the year 2014.
The Chairman of Supervisory Board, Pavlo Zebrivsky, in his speech highly appreciated the Company’s activities in the year 2013. Viktoria Smarodina, Chief Financial Officer, and Dmytro Taranchuk, Head of Legal Department, also reported on the issues on the meeting agenda.
All the issues on the agenda of a regular Meeting of Shareholders of Farmak JSC have been determined.
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...